The Phase I clinical trial of the first genital warts vaccine (HPV 6/11 vaccine) in China is recently initiated in the Liuzhou city of Guangxi province, March 26, 2015. This HPV6/11 vaccine, with the commercial name Gecolin?, is co-developed by Xiamen University, Xiamen INNOVAX Biotech and its parent company Beijing Wantai Biopharma. The development of Gecolin? is based on an innovative E.coli expression platform, with which Xiamen INNOVAX has successfully developed the world’s first Hepatitis E vaccine Hecolin? and a human papillomavirus (type 16/18) vaccine Cecolin?. The initiation of the phase I clinical trial of Gecolin? indicates that INNOVAX has continued to lead in the field of HPV vaccine in China.
Genital warts are symptoms of a highly contagious sexually transmitted disease caused by some types of human papillomavirus (HPV). It is spread through direct skin-to-skin contact, usually during oral, genital, or anal sex with an infected partner (From Wikipedia). In China, genital warts is the third most common STD (sexually transmitted disease). Genital warts vaccine can induce high titer of neutralizing antibodies in recipients, thus provide continuous immune-protection and efficiently prevent genital warts in most cases for vaccine recipients and their partners.